RT Journal Article SR Electronic T1 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? JF British Journal of Ophthalmology JO Br J Ophthalmol FD BMJ Publishing Group Ltd. SP 1332 OP 1337 DO 10.1136/bjophthalmol-2021-319530 VO 106 IS 10 A1 Ari Stoner A1 Alon Harris A1 Francesco Oddone A1 Aditya Belamkar A1 Alice Chandra Verticchio Vercellin A1 Joshua Shin A1 Ingrida Januleviciene A1 Brent Siesky YR 2022 UL http://bjo.bmj.com/content/106/10/1332.abstract AB Carbonic anhydrase inhibitors (CAIs) have been used for many decades in the treatment of glaucoma. Systemic CAIs were an early treatment option to lower intraocular pressure by reducing aqueous humour production; however, frequent side effects including polyuria and paresthesia contributed to the eventual development of topical CAIs. As topical drug development evolved over time, prostaglandin analogues and beta-blockers have become the gold standard of glaucoma therapies. Although prescribed less often than other classes of topical glaucoma therapies, topical CAIs continue to be used in combination therapies with beta-blockers and alpha agonists. Topical CAIs have also been demonstrated to alter biomarkers of ocular haemodynamics, which have relevance in glaucoma. The purpose of this review is to review and summarise the current state of topical CAI prescribing trends, known efficacy and suggested mechanisms and potential influence on ocular haemodynamics for the future of glaucoma management.